Soterix Medical announced today that it began patient recruitment for a trial of its treatment-resistant depression treatment. The company intends to enroll individuals who received but did not adequately respond to repetitive Transcranial Magnetic Stimulation (rTMS). Woodbridge, New Jersey-based Soterix, with technology licensed from Columbia University, develops a cloud-based targeting software. The system, based on […]
Soterix Medical
Soterix wins IDE for depression treatment trial
Soterix Medical announced today that it received FDA investigational device exemption (IDE) to launch a trial of its tDCS-LTE) neuromodulation system. New York-based Soterix Medical’s transcranial direct current stimulation-limited total energy (tDCS-LTE) system is an at-home platform for people suffering from major depressive disorder (MDD). The proprietary technology is designed to support the home-based tDCS, […]
Soterix Medical launches tDCS trial for cocaine addiction
Soterix Medical said yesterday that it won a Phase I NIH-SBIR contract from the National Institute of Health’s National Institute of Drug Abuse to launch a trial of its remote transcranial direct current stimulation platform intended to treat cocaine addiction. The Phase I contract comes with a value of approximately $475,000 delivered over a period of […]
Soterix touts transcranial stim depression trial results
Soterix Medical today released results from trials of its direct current stimulation-limited total energy technology designed to treat depression, touting that the device was found to be safe and effective with improvements in depression-rating metrics lasting for a month after treatment. The tDCS-LTE system is designed to deliver energy to the dorsolateral prefrontal cortex region […]
Soterix Medical wins FDA 510(k) for IontoDC
Soterix Medical said today it won FDA 510(k) clearance for its IontoDC device designed to use direct current to introduce ions of soluble salts and other drugs into the body. The New York-based company said that the newly-cleared IontoDC device provides 10, 20, 30 or 40 minutes of direct current at intensities varying between 1 and […]
Soterix Medical wins Health Canada approval, launches PainX tDCS
Soterix Medical said today it won Health Canada approval for and launched its PainX transcranial direct current stimulation technology designed for treating pain disorders in adults. The PainX tDCS system is a non-invasive, battery-powered device designed to deliver mild current to a specific section of the cerebral cortex to modulate reaction to painful experiences or control pain […]
Soterix Medical wins CE Mark for tDCS depressive disorder therapy
Depression-treating neuromod developer Soterix Medical said yesterday it won CE Mark approval in the European Union for its 1×1 tDCS therapy system designed to treat major depressive disorder. The 1×1 tDCS system is a non-invasive therapeutic device that uses low-intensity direct current to stimulate a region of the cerebral cortex that controls mood, according to […]